Payment overview · 2025
General Payments
$203.26
11 reported records · 5 companies
Healthcare provider profile · identity verified
Don Gregory Bell, MD
Allopathic & Osteopathic Physicians|Family Medicine · COUSHATTA, LA · NPI 1912935727
Verified facts
What the public records show
CMS Open Payments records show Don Gregory Bell, MD received $203.26 in general payments during 2025 across 11 reported records.
Dexcom, Inc. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $61.70 | 30.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.97 | 22.6% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.87 | 17.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.73 | 15.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.99 | 14.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $203.26 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $61.70 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.97 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $34.87 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.73 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.99 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 398 | 65 |
| Lisinopril | Lisinopril | 388 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 357 | 71 |
| Metformin Hcl | Metformin Hcl | 329 | 59 |
| Gabapentin | Gabapentin | 317 | 68 |
| Meloxicam | Meloxicam | 281 | 76 |
| Omeprazole | Omeprazole | 277 | 67 |
| Losartan Potassium | Losartan Potassium | 258 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 255 | 50 |
| Sertraline Hcl | Sertraline Hcl | 215 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 210 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 191 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 35 |
| Furosemide | Furosemide | 174 | 45 |
| Clonazepam | Clonazepam | 164 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 28 |
| Tramadol Hcl | Tramadol Hcl | 153 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 32 |
| Simvastatin | Simvastatin | 147 | 28 |
| Azithromycin | Azithromycin | 146 | 110 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 23 |
| Glipizide | Glipizide | 116 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 23 |
| Montelukast Sodium | Montelukast Sodium | 103 | 20 |
| Potassium Chloride | Potassium Chloride | 103 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 17 |
| Prednisone | Prednisone | 100 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 22 |
| Carvedilol | Carvedilol | 94 | 20 |
| Alprazolam | Alprazolam | 92 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 85 | 61 |
| Atenolol | Atenolol | 84 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 14 |
| Eliquis | Apixaban | 80 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 22 |
| Jardiance | Empagliflozin | 79 | 16 |
| Nifedipine Er | Nifedipine | 74 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 33 |
| Trazodone Hcl | Trazodone Hcl | 64 | suppressed |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 59 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 13 |
| Amoxicillin | Amoxicillin | 54 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Fluconazole | Fluconazole | 51 | 22 |
| Cephalexin | Cephalexin | 49 | 40 |
| Dexamethasone | Dexamethasone | 49 | 40 |
| Finasteride | Finasteride | 49 | suppressed |
| Celecoxib | Celecoxib | 48 | 11 |
| Mounjaro | Tirzepatide | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 31 |
| Allopurinol | Allopurinol | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 12 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Famotidine | Famotidine | 41 | suppressed |
| Estradiol | Estradiol | 40 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 34 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Temazepam | Temazepam | 34 | suppressed |
| Mupirocin | Mupirocin | 32 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 21 |
| Methimazole | Methimazole | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 15 |
| Ondansetron Odt | Ondansetron | 29 | 17 |
| Risperidone | Risperidone | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 17 | 17 |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Ethosuximide | Ethosuximide | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 11 |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Topamax | Topiramate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $203.26 · 11 records | Dexcom, Inc. | Auvelity, Dexcom G6 Transmitter, ELIQUIS, GVOKE HYPOPEN, Kerendia, NURTEC ODT | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error